Neurotrophic Growth Factors in Breast Milk

Sponsor
Istanbul University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05943847
Collaborator
(none)
25
1
14.3
1.7

Study Details

Study Description

Brief Summary

The goal of this observational study is to demonstrate the presence of neurotrophic factors in the breast milk of mothers with 18-month-old children and the persistence of these factors in breast milk after the age of 2 years. The main questions it aims to answer are:

  • Does the breast milk of mothers with 18-month-old babies contain Brain-Derived Neurotrophic Factor (BDNF), S100B protein and glial cell line-derived neurotrophic factor (GDNF)?

  • Does the breast milk continue to contain BDNF, s100B protein and GDNF and-after 24 months?

Participants will be asked to give breastmilk at 3 separate times. Breast milk samples will be collected from mothers at 18th-month, 24th-month and ≥25 months of their babies. A total of 75 breast milk samples obtained from 25 mothers with their consent will be analyzed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Growth factors are among the bioactive compounds found in breast milk and have effects on the growth and maturation of the baby's organs and systems. The completion of each organ maturation occurs at different times. Although the development of the nervous system reaches 60% of adults at the age of 2 years, it continues after the age of 2. Brain-Derived Neurotrophic Factor (BDNF), S100B protein, and glial cell line-derived neurotrophic factor (GDNF) are the neurotrophic growth factors found in breast milk and play a critical role in the development of the nervous system, the maintenance of neuronal functionality and the proliferation of neurons . They play a role during brain development, particularly in differentiating neuronal and glial cells. In addition, it is effective in synaptic plasticity and has important roles in the mature nervous system. The presence of neurotrophic factors in breast milk under the age of one has been demonstrated. However, the presence of these factors in breast milk has not been evaluated at 2 years and above. In this study, we aimed to demonstrate the presence of neurotrophic factors in the breast milk of mothers with 18-month-old children and the persistence of these factors in breast milk after the age of 2 years.

    Study Design:

    The study was conducted at Istanbul University, Istanbul Medical Faculty, Department of Pediatrics, Department of Social Pediatrics, Well Child Outpatient Clinic. All mothers participating in the study are informed in detail about the study and the importance of breast milk. According to Turkish Demographic and Health Survey (TDHS) 2018 data, the rate of breastfeeding is 66% at 12 months, 50% at 18 months, and 34% at 24 months. Considering the decrease according to age, it was assumed that the breastfeeding rate would be 18% after the age of 2. Considering the TDHS 2018 data of mothers, assuming that 18% of mothers breastfeed their babies after the age of 2, with a 95% confidence level and an acceptable sampling error of 0.15, the sample size calculation formula was used to estimate the population ratio, and the sample size was calculated for each mother. It is planned to have at least 25 mothers during the milk collection period (for each mother 18., 24., ≥ 25 months), with a total of 75 breast milk.

    Breast milk collections and analysis:
    1. Breast milk will be collected at 3 separate times at 18th-month, 24th-month and ≥25 months of their babies.

    2. Using the manual milking method, 5 ml of expressed breast milk will be collected in Eppendorf tubes and transported in a polystyrene box containing ice (at 4°C) to the laboratory within 30 minutes. All breast milk samples will be stored at -20°C under laboratory conditions until the analysis.

    3. All collected breast milk samples will be prepared for analysis by gradual thawing (breast milk will be taken to +4 C degrees one day before analysis, room temperature on the day of analysis) at the 12th month of the study. The neurotrophic factors (BDNF, S100B, GDNF) will be analyzed with ELISA (Elabsicence; United States) method.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    25 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of Neurotrophic Growth Factors in Breast Milk at Two Years of Age and Beyond
    Actual Study Start Date :
    Mar 24, 2023
    Anticipated Primary Completion Date :
    Mar 25, 2024
    Anticipated Study Completion Date :
    Jun 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Analysis of neurotrophic growth factors at 18 months [Sample collection: 1-3 months of the study ; Analyze: 12th month of the study]

      Breast milk samples which were collected at the 18th month of the babies and stored in Eppendorf tubes at -20°C will be prepared for analysis by gradual thawing (breast milk will be taken to +4 C degree the day before analysis, room temperature on the day of analysis) in the 12th month of the study and will be analysed for BDNF, GDNF neurotrophic factors and s100B protein with ELISA (E-lab-science; United States) method.

    2. Analysis of neurotrophic growth factors at 24 months [Sample collection: 7-9 months of the study ; Analyze: 12th month of the study]

      Breast milk samples which were collected at the 24th month of the babies and stored in Eppendorf tubes at -20°C will be prepared for analysis by gradual thawing (breast milk will be taken to +4 C degree the day before analysis, room temperature on the day of analysis) in the 12th month of the study and will be analysed for BDNF, GDNF neurotrophic factors and s100B protein with ELISA (E-lab-science; United States) method.

    3. Analysis of neurotrophic growth factors at ≥25 months [Sample collection: 8-11 months of the study ; Analyze: 12th month of the study]

      Breast milk samples which were collected after 24th month of the babies and stored in Eppendorf tubes at -20°C will be prepared for analysis by gradual thawing (breast milk will be taken to +4 C degree the day before analysis, room temperature on the day of analysis) in the 12th month of the study and will be analysed for BDNF, GDNF neurotrophic factors and s100B protein with ELISA (E-lab-science; United States) method.

    Secondary Outcome Measures

    1. Sociodemographic factors [at the beginning (18. months of age)]

      Maternal age, number of pregnancies, number of births

    2. Maternal disease [at the beginning (18. months of age)]

      Rate of mothers' diseases other than exclusion criteria, if any

    3. Maternal drug use [at the beginning (18. months of age)]

      Rate of medications used by mothers, if any

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Mothers who applied for the 18th-month follow-up of their exclusively breastfed baby for the first 6 months agreed to participate in the study.
    Exclusion Criteria:
    • Mothers of infants who were not exclusively breastfed in the first six months

    • Mothers with infection, metabolic disease, central nervous system, breast disease or pregnancy

    • Mothers of infants with infection, metabolic disease, malnutrition and central nervous system disease

    • Mothers who stop breastfeeding before 25 months

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 İstanbul University İstanbul Medical Faculty Department of Pediatrics Division of Social Pediatrics Istanbul Turkey

    Sponsors and Collaborators

    • Istanbul University

    Investigators

    • Study Director: Gonca Keskindemirci, Assoc Prof, İstanbul Univeristy
    • Principal Investigator: Öykü Özbörü Aşkan, PhD, İstanbul Univeristy
    • Principal Investigator: Gülbin Gökçay, Prof, İstanbul Univeristy
    • Principal Investigator: Tülin Özden, Prof, İstanbul Univeristy
    • Principal Investigator: Alev Bakır Kayı, PhD, İstanbul Univeristy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gonca Keskindemirci, Assoc Prof, Istanbul University
    ClinicalTrials.gov Identifier:
    NCT05943847
    Other Study ID Numbers:
    • TSA-2023-39668
    First Posted:
    Jul 13, 2023
    Last Update Posted:
    Jul 13, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Gonca Keskindemirci, Assoc Prof, Istanbul University

    Study Results

    No Results Posted as of Jul 13, 2023